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A B S T R A C T
Background
Subfertility affects 15% to 20% of couples trying to conceive. In vitro fertilisation (IVF) is one of the assisted reproduction techniques
developed to improve chances of achieving pregnancy. In the standard IVF method with controlled ovarian hyperstimulation (COH),
growth and development of multiple follicles are stimulated by using gonadotrophins, often combined with a gonadotrophin-releasing
hormone (GnRH) agonist or antagonist. Although it is an established method of conception for subfertile couples, the treatment is
expensive and has a high risk of adverse effects. Studies have shown that IVF in a natural cycle (NC) or a modified natural cycle (MNC)
might be a promising low risk and low cost alternative to the standard stimulated IVF treatment since the available dominant follicle
of each cycle is used. In this review, we included available randomised controlled studies comparing natural cycle IVF (NC and MNC)
with standard IVF.
Objectives
To compare the efficacy and safety of natural cycle IVF (including both NC-IVF and MNC-IVF) with controlled ovarian hyperstim-
ulation IVF (COH-IVF) in subfertile couples.
Search methods
An extended search including of the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, ClinicalTrials.gov, conference abstracts in the Web of Knowledge,
the World Health Organization International Trials Registry Platform search portal, LILACS database, PubMed and the OpenSIGLE
database was conducted according to Cochrane guidelines. The last search was on 31st July 2013.
Selection criteria
All randomised controlled trials (RCTs) comparing either natural cycle IVF or modified natural cycle IVF versus standard IVF in
subfertile couples were included.
Data collection and analysis
Data selection and extraction and risk of bias assessment were carried out independently by two authors (TA and AC). The primary
outcome measures were live birth rate and ovarian hyperstimulation syndrome (OHSS) rate per randomised woman. We calculated
Mantel-Haenszel odds ratios for each dichotomous outcome and either themean difference or the standardised mean difference (SMD)
for continuous outcomes, with 95% confidence intervals (CIs). A fixed effect model was used unless there was substantial heterogeneity,
in which case a random effects model was used.
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Main results
Six randomised controlled trials with a total of 788 women were included. The largest of these trials included 396 women eligible for
this review.
No evidence of a statistically significant difference was found between natural cycle and standard IVF in live birth rates (OR 0.68, 95%
CI 0.46 to 1.01, two studies, 425 women, I2= 0%, moderate quality evidence). The evidence suggests that for a woman with a 53%
chance of live birth using standard IVF, the chance using natural cycle IVF would range from 34% to 53%. There was no evidence of a
statistically significant difference between natural cycle and standard IVF in rates of OHSS (OR 0.19, 95% CI 0.01 to 4.06, one study,
60 women, very low quality evidence), clinical pregnancy (OR 0.52 95% CI 0.17 to 1.61, 4 studies, 351 women, I2=63%, low quality
evidence), ongoing pregnancy (OR 0.72, 95% CI 0.50 to 1.05, three studies, 485 women, I2=0%, moderate quality evidence), multiple
pregnancy (OR 0.76, 95% CI 0.25 to 2.31, 2 studies, 527 women, I2=0%, very low quality evidence), gestational abnormalities (OR
0.44 95% CI 0.03 to 5.93, 1 study, 18 women, very low quality evidence) or cycle cancellations (OR 8.98, 95% CI 0.20 to 393.66, 2
studies, 159 women, I2=83%, very low quality evidence). One trial reported that the oocyte retrieval rate was significantly lower in the
natural cycle group (MD -4.40, 95% CI -7.87 to -0.93, 60 women, very low quality evidence). There were insufficient data to draw
any conclusions about rates of treatment cancellation. Findings on treatment costs were inconsistent and more data are awaited. The
evidence was limited by imprecision. Findings for pregnancy rate and for cycle cancellation were sensitive to the choice of statistical
model: for these outcomes, use of a fixed effect model suggested a benefit for the standard IVF group. Moreover the largest trial has
not yet completed follow up, though data have been reported for over 95% of women.
Authors’ conclusions
Further evidence from well conducted large trials is awaited on natural cycle IVF treatment. Future trials should compare natural cycle
IVF with standard IVF. Outcomes should include cumulative live birth and pregnancy rates, the number of treatment cycles necessary
to reach live birth, treatment costs and adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Natural cycle in vitro fertilisation for subfertile couples
Review question: To determine whether in vitro fertilisation (IVF) in a natural cycle is a good alternative to standard IVF for subfertile
couples.
Background: Assisted reproduction techniques such as IVF can help subfertile women to achieve a pregnancy. In IVF, an egg is fertilised
in a laboratory and placed back in the woman’s uterus. Different IVF protocols have been developed since the first IVF in 1978 including
natural cycle IVF (without hyperstimulation of the ovaries), modified natural cycle IVF (with low dose ovarian hyperstimulation) and
IVF with controlled ovarian hyperstimulation. The aim of this systematic review was to assess the efficacy and safety of natural cycle
IVF and modified natural cycle IVF compared with controlled ovarian hyperstimulation IVF in subfertile couples.
Study characteristics: Six trials were included, with a total of 788 women undergoing an IVF treatment. The evidence is current to
31st July 2013. The largest trial in the review (with 396 women) has not yet reported full results.
Key points: The evidence suggested that for a woman with a 53% chance of live birth using standard IVF, the chance using natural
cycle IVF ranges from 34% to 53%. No significant difference was found in rates of clinical pregnancy, ongoing pregnancy, multiple
pregnancy, incidence of ovarian hyperstimulation syndrome, gestational abnormalities or cancellations of treatment. However findings
were imprecise for all outcomes and further evidence from larger studies is awaited. There was evidence from single studies that a lower
number of oocytes was retrieved in the natural cycle group. Findings on cost-effectiveness were inconsistent.
Quality of evidence: Quality ratings for the evidence ranged from very low to moderate, the main limitation being imprecision due to
insufficient data. When the review authors checked the effect of using an alternative method of analysis the findings suggested higher
rates of clinical pregnancy with standard IVF than with natural cycle IVF.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
DRAFT Natural cycle IVF versus standard IVF for subfertile couples
Patient or population: Subfert ile couples
Settings: Assisted reproduct ive technology
Intervention: Natural cycle IVF versus standard IVF
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* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).




























































































GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Serious imprecision: conf idence intervals compatible with no dif ference between the intervent ions or with substant ial benef it
f rom standard IVF
2 Very serious imprecision, did not describe methods of allocat ion concealment or sequence generat ion in all cases
3 High risk of attrit ion bias in one study





























































































B A C K G R O U N D
Description of the condition
Subfertility is defined as not achieving pregnancy after a period
of 12 months of intercourse with the same partner without con-
traception. Subfertility affects 15% to 20% of couples trying to
conceive (Evers 2002; Heineman 2011). Assisted reproduction
techniques (ART) have been developed to improve the chance of
achieving pregnancy. In vitro fertilisation (IVF) is one approach,
where an oocyte and spermatozoa are merged in a laboratory set-
ting before being implanted in the uterus. Although initially IVF
was used mostly for women with tubal subfertility (Leeton 1982),
the indications were soon expanded to include couples with men-
strual cycle disorders, tubal abnormalities and male subfertility as
well unexplained subfertility (Heineman 2011). For IVF, stimu-
lating follicle growth and retrieval of the oocytes are necessary,
for which several different methods are used. The first successful
IVF treatment was performed in 1978 in an unstimulated natu-
ral cycle. Although pregnancies did occur with early natural cycle
IVF (NC-IVF), the success rates were low secondary to luteinis-
ing hormone (LH) surges which induced ovulation and resulted
in cancellations (Rongieres-Bertrand 1999). The introduction of
controlled ovarian hyperstimulation (COH) IVF (COH-IVF) led
to it becoming the standard ovarian stimulation method because
of the improved success rates (Pelinck 2009).
Although COH-IVF increases pregnancy rates, it also meant an
increase in costs and complications, mainly due to ovarian hyper-
stimulation syndrome (OHSS) and multiple pregnancies. Up to
10 or more oocytes could be retrieved, however the oocyte best
suited for fertilisation based on morphology could be selected,
which may have improved the success rate of the treatment (Rosen
2008; Wang 2011). Other technical improvements such as cry-
opreservation and vitrification (Geraedts 2012) have meant that
oocytes could be preserved so that women do not have to repeat
the full COH treatment when implantation of a fresh embryo
fails. Initially IVF had live birth rates of less than 16% per trans-
fer (Naaktgeboren 1985), but now most clinics are reporting live
birth rates of 20% to 25% per started cycle for women under the
age of 40 years (Heineman 2011).
With the development of gonadotrophin-releasing hormone
(GnRH) antagonists, a new IVF treatment was developed, known
as modified natural cycle IVF (MNC-IVF), with fewer complica-
tions and risks compared to COH protocols (Rongieres-Bertrand
1999). Because of this improvement in ovarian stimulation and
also improved laboratory techniques such as the culture media,
NC-IVF has again been considered as an option. However, more
MNC or NC treatments are likely to be necessary in order to
obtain pregnancy rates comparable to COH-IVF (Pelinck 2009).
Overall, the treatment costsmight be lower inNC-IVF andMNC-
IVF compared to COH-IVF, but it may cost the woman more
effort to reach pregnancy because of the lower pregnancy rate per
treatment and the need to repeat treatment cycles. On the other
hand, the side effects of the hormone treatment and the emotional
distress of stimulated IVF are often perceived as unacceptable and
people seem to prefer the simplicity and short duration of a low
stimulation treatment (Hojgaard 2001; Verberg 2008).
Description of the intervention
In both NC-IVF and MNC-IVF, the treatment cycles of women
with a normal menstrual function are monitored in order to mea-
sure the follicle structure and endometrial morphology. When the
follicle reaches an estimated size of 15 to 20mm, human chorionic
gonadotrophin (hCG) is administered intramuscularly and final
maturation of the oocyte is thereby induced (Nargund 2001). The
oocyte is then retrieved by aspirating the follicle under vaginal ul-
trasound guidance.
The potential advantages of both NC-IVF and MNC-IVF are the
following:
• the almost complete absence of multiple pregnancies;
• the very low risk of ovarian hyperstimulation syndrome;
• the reduced length of stimulation;
• the reduction in both physical and emotional stress as
ovarian stimulation is not used or only used as a very low-dose
protocol;
• the reduced costs;
• no resting cycle is needed following a failed cycle (Pelinck
2002).
Cryopreservation after MNC-IVF and NC-IVF is generally not
possible, so there are no embryos available for freezing. Therefore
NC-IVF and MNC-IVF may be preferable for couples who ob-
ject to embryo freezing for cultural or religious reasons, or where
cryopreservation of embryos is illegal.
The potential disadvantages of NC-IVF include:
• a higher cancellation rate (due to premature LH surges);
• the lowered chances of a live birth per started cycle;
• the lowered chances of embryo transfer after a thawed cycle.
Natural cycle IVF mimics the body’s natural processes, such as
alterations to the endometrium in preparation for implantation.
The treatment is physically less demanding than the COH treat-
ment, and usually no resting cycle is necessary after a failed treat-
ment. The treatment can therefore be repeated in the following
cycle. However, because only one oocyte is retrieved, and therefore
only one embryo is implanted, the pregnancy rates per woman per
cycle are low at 6% to 7% (Pelinck 2002; Zayed 1997).
How the intervention might work
There are two types of natural cycle IVF.
1. Natural cycle-IVF (NC-IVF)
• In NC-IVF no drugs are administered
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• From the moment the follicle approaches maturity (follicle
size 10 mm approximately), the oocyte is monitored and the
retrieval date is planned
• Ovulation triggering with hCG administration is given
when the follicle size is 15 to 20 mm or when the serum estradiol
rises, or both (Pelinck 2009)
• In the case of LH surge (measured in urine), either
cancellation or advancement of oocyte retrieval occurs (Zayed
1997)
2. Modified natural cycle-IVF (MNC-IVF)
• In MNC-IVF gonadotrophin protocols are used to
stimulate follicular growth. Different protocols start
administering follicle stimulating hormone (FSH) at different
stages in the cycle but all protocols use a similar short
stimulation period of two to six days
• After up to six days of ovarian stimulation or when the
largest follicle reaches a diameter of 14 mm (number of days
varies according to differing protocols), then GnRH antagonists
are administered to suppress LH secretion (in order to prevent
premature ovulation)
• When the leading follicle reaches a size of at least 15 to 20
mm, ovulation is triggered in the same manner as in COH-IVF
but only one oocyte is fully grown and retrieved
Regardless of the immediate pituitary recovery after discontinuing
the GnRH antagonist, luteal phase support improves pregnancy
rates for MNC-IVF (Chavez-Badiola 2011).
Both MNC-IVF and NC-IVF have oocyte retrieval performed in
the same manner as COH-IVF; that is, with vaginal ultrasound
and usually under mild sedation.
In COH-IVF, FSH is administered to stimulate the growth of five
to 15 follicles. To prevent early oocyte maturation caused by pre-
mature LH production, a GnRH agonist is used for suppressing
the pituitary release of both LH and FSH. Down-regulation by
continuous administration first causes LH and FSH hypersecre-
tion followed by depletion of the pituitary store and desensitisa-
tion after approximately 10 days.
• In the ’long protocol’ down-regulation begins in the cycle
prior to the treatment cycle.
• In the ’short’ or ’flare-up protocol’ the GnRH agonist is
administered from day one of the treatment cycle.
• In the ’ultrashort protocol’ only three doses of the agonist
are used (Elder 2011).
As an alternative to the GnRH agonist, a GnRH antagonist can
be used to prevent the LH surge in COH. The antagonist binds to
and immediately blocks receptors in the pituitary, directly inhibit-
ing the release of gonadotrophins. Different protocols for GnRH
antagonist administration using different doses are used, varying
from multiple-dose fixed (0.25 mg daily from day six to seven of
stimulation) to single-dose (single administration of 3 mg on day
seven to eight of stimulation) (Al-Inany 2011).
When two ormore follicles reach a size of 18 to 20mm (Heineman
2011), hCG is administered for the final maturation. Finally, 34 to
36 hours after hCG administration, the oocyte retrieval procedure
is performed. This is done transvaginally under vaginal ultrasound
guidance and usually with mild sedation.
All of these IVF techniques aim to retrieve one or more oocytes
suitable for fertilisation.
Why it is important to do this review
When choosing between different IVF protocols, couples need to
balance the benefits and harms. Standard protocol IVF is thought
to be associated with higher birth rates than the natural cycle treat-
ments, but it is closely linked with complications such as OHSS
and multiple pregnancies. Evidence from studies has suggested
that natural cycle IVF is a low-risk, low-cost (to the patient) and
patient-friendly procedure, although results have often been based
on small study populations. Furthermore, studies comparing NC-
IVF, MNC-IVF and COH-IVF report different outcomes. Based
on previous studies, natural cycle IVF seems a low-risk and low-
cost procedure, preferred by women and physicians (Pelinck 2009;
Pistorius 2006; Reyftmann 2007). This review evaluated the evi-
dence from randomised controlled trials on NC-IVF, MNC-IVF
and COH-IVF.
O B J E C T I V E S
To compare the efficacy and safety of natural cycle IVF (includ-
ing both NC-IVF andMNC-IVF) with controlled ovarian hyper-
stimulation IVF (COH-IVF) in subfertile couples.
M E T H O D S
Criteria for considering studies for this review
Types of studies
In this review we included only truly randomised controlled tri-
als (RCTs) comparing natural cycle IVF with COH-IVF. In this
review, natural cycle IVF included both NC-IVF and MNC-IVF.
Crossover trials were included but only the data from the first
phase were included in meta-analyses.
Types of participants
Inclusion criteria
• No age restriction
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• Subfertile women and couples undertaking an IVF
treatment
• Both male and female factor subfertility
• Both nulliparous and multiparous women
• With or without a previous IVF treatment
Exclusion criteria
• Donor oocytes
• Frozen embryo transfer
• Animal studies
Types of interventions
1. All trials comparing either NC-IVF or MNC-IVF with COH-
IVF were eligible for inclusion.
2. All trials comparing different protocols of MNC-IVF were also
eligible for inclusion.
Types of outcome measures
Primary outcomes
Effectiveness: live birth rate per woman, defined as the delivery of
one or more living fetuses after 20 completed weeks of gestation.




• pregnancy rate per woman defined as the successful
implantation of a fetus, confirmed by the visualisation of a
gestational sac. Cumulative measures will be preferred
• ongoing pregnancies per woman, defined as the confirmed
presence of a gestational sac and a fetal heart beat after 12 weeks
gestation;
• number of oocytes retrieved per woman;
• time from start of treatment to live birth;
• number of cycles required to conceive per woman
Adverse effects:
• multiple pregnancies per woman
• lack of embryos for cryopreservation;
• cycle cancellation rates per woman;
• gestational abnormalities (ectopic pregnancy, fetal growth
disorders, preterm births and miscarriages) per woman;
• cancellation of the treatment, due to patient motivation or
adverse effects;
• cost effectiveness, evaluating the total costs to reach
pregnancy in the different IVF treatments.
Cumulative measures of effectiveness were preferred, due to the
difference in number of oocytes retrieved, and because a COH-
IVF treatment is a much greater burden for the patient and there-
fore cannot be repeated as often as a natural cycle IVF treatment.
Search methods for identification of studies
We searched for all published and unpublished randomised con-
trolled trials, studying either NC-IVF orMNC-IVF versus COH-
IVF. We used the following search strategies, in consultation
with the Cochrane Menstrual Disorders and Subfertility Group
(MDSG) Trials Search Co-ordinator. We applied no language re-
strictions.
Electronic searches
We searched the following databases to 31 July 2013:
• Menstrual Disorders and Subfertility Group Specialised
Register (MDSG) (Appendix 1);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (Ovid) (Appendix 2);
• MEDLINE® In-Process & Other Non-Indexed Citations,
MEDLINE® Daily and MEDLINE® (Ovid) (Appendix 3);
• EMBASE (Ovid) (Appendix 4);
• PsycINFO (Ovid) (Appendix 5);
• CINAHL (EBSCOhost) Appendix 6).
Other electronic sources of trials included the following.
• Trial registers for ongoing and registered trials:
’ClinicalTrials.gov’, a service of the US National Institutes of
Health (http://clinicaltrials.gov/ct2/home) and World Health
Organization International Clinical Trials Registry Platform
search portal (http://www.who.int/trialsearch/Default.aspx)
(Appendix 7).
• Conference abstracts in the Web of Knowledge (http://
wokinfo.com/) (Appendix 8).
• LILACS database as a source of trials from the Portuguese
and Spanish-speaking world (htpp://regional.bvsalud.org/php/




• OpenSIGLE database for grey literature from Europe (http:
//opensigle.inist.fr/).
We used EndNote to manage the search results. The MEDLINE
randomised controlled trial filter was the Cochrane highly sensi-
tive search strategy for identifying randomised controlled trials,
which is found in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011), whereas the EMBASE filter has
been developed by the Scottish Intercollegiate Guidelines Net-
work (SIGN).
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Searching other resources
In order to obtain additional relevant data, we examined reference
lists of eligible articles and contacted the study authors where nec-
essary. Professor Cindy Farquhar andDr Astrid Cantineau acted as
experts on different IVF treatments, and we requested additional
information about unpublished trials from the authors. We hand-
searched non-indexed journals in collaboration with theCochrane
Menstrual Disorders and Subfertility Group Trials Search Co-or-
dinator.
Data collection and analysis
Selection of studies
TA and AC independently scanned the titles and abstracts of the
articles retrieved by the search. Those judged to be irrelevant were
removed while the full texts of potentially eligible articles were
retrieved and independently examined by the two authors. They
assessed the full-text articles according to the inclusion criteria and
selected those eligible for inclusion in the review. Any doubts or
disagreements regarding the inclusion of an article were discussed
with CF in order to reach an acceptable compromise.
Data extraction and management
The authors designed and pilot tested a data extraction form. We
included the following characteristics of included studies in the ex-
traction form:methods, participants, interventions and outcomes.
Both authors trained with the extraction form using a representa-
tive sample of the studies to be reviewed and, in case of disagree-
ment, achieved a consensus in consultation with a third author.
Where necessary, we modified the extraction form. If studies were
reported in more than one publication, we extracted data from the
different reports directly into a single data extraction form so that
no data would be missed.
Assessment of risk of bias in included studies
TheCochraneCollaboration’s recommended tool for assessing risk
of bias is a domain-based evaluation (Higgins 2011). Assessments
were made for the following domains:
• selection bias (random sequence generation and allocation
concealment);
• performance bias (blinding of participants and personnel);
• detection bias (blinding of outcome assessment);
• attrition bias (incomplete outcome data);
• reporting bias (selective reporting);
• other bias.
These assessments were:
• high risk of bias;
• unclear risk of bias;
• low risk of bias.
Measures of treatment effect
For dichotomous data (for example live birth rate, pregnancy rate,
ongoing pregnancy rate, failure to freeze embryos, cycle cancel-
lation, cancellation of treatment, OHSS, multiple pregnancies,
number of cycles required to conceive, gestational abnormalities
or cumulative pregnancy or live birth rate) we used the numbers
of events in the control and intervention groups of each study to
calculateMantel-Haenszel odds ratios (ORs). For continuous data
(for example number of oocytes retrieved per woman or time from
start of treatment to live birth), if all studies reported exactly the
same outcomes we calculated mean differences (MDs) between
treatment groups. If similar outcomes were reported on different
scales (for example cost effectiveness) we calculated the standard-
ised mean difference (SMD). We reversed the direction of effect of
individual studies, if required, to ensure consistency across trials.
We presented 95% confidence intervals for all outcomes. Where
data to calculate ORs or MDs were not available, we utilised the
most detailed numerical data available that may facilitate similar
analyses of included studies (for example test statistics, P values).
We compared the magnitude and direction of effect reported by
studies with how they were presented in the review, taking account
of legitimate differences.
Unit of analysis issues
The unit of primary analysis was per woman randomised to the in-
tervention or control groups. For the primary analysis, we counted
multiple live births as one live birth event. From the included
crossover study, we only used the data up to the crossover point.
Dealing with missing data
Where relevant data were missing from one of the included stud-
ies, we tried to contact the original investigator to request themiss-
ing data. If the missing data were unobtainable, the authors deter-
mined whether the data were missing at random or not and were
adjusted accordingly (Higgins 2011). The potential impact was
reported in the ’Discussion’ section. Where live birth was men-
tioned as an outcome measure but not reported in the results sec-
tion, we assumed an (ongoing) pregnancy did not occur. For the
secondary outcomes, we only analysed the available data. When
assumptions were made, we performed sensitivity analyses to as-
sess how sensitive results were to reasonable changes.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity and when
study participants, interventions and outcomes were judged to
be sufficiently similar, we conducted a meta-analysis to provide a
meaningful summary. We assessed statistical heterogeneity by vi-
sually inspecting the plot and using the I² statistic. We interpreted
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the results of the I² statistic according to the Higgins 2011; an I2
greater than 50%was judged to indicate substantial heterogeneity.
Assessment of reporting biases
In order to minimise the impact of reporting biases, we conducted
an extensive search for eligible articles and we carefully inspected
the included articles for reporting biases, such as publication bias,
duplication bias or outcome reporting bias. Where possible, we
compared outcomes reported in final published studies with pre-
planned outcomes reported in published protocols, and contacted
the original investigator where necessary. We included unpub-
lished data by searching for it or by contacting the original inves-
tigator. We did not construct a funnel plot since there were only
five included trials.
Data synthesis
We used a fixed-effect model to calculate pooled ORs and 95%
CIs. If moderate to considerable heterogeneity was identified, we
used a random-effects model. Where some studies measured mul-
tiple cycles and some reported only one cycle data were pooled but
were stratified according to whether multiple or single cycles were
reported.
Subgroup analysis and investigation of heterogeneity
We considered clinical differences between the studies where het-
erogeneity was found. If more data had been available, we would
have conducted subgroup analyses in the following subgroups in
order to investigate heterogeneous results:
• Cause of subfertility, grouped by unexplained subfertility,
male factor subfertility, tubal disease and ovulation disorder.
• Age, < 38 years or > 38 years.
• Prior treatment, if the patient had had an IVF treatment
before.
• Intervention, grouped by NC-IVF or MNC-IVF
However, data were too few for the planned subgroup analysis to
be feasible, except for type of intervention.
Sensitivity analysis
We conducted sensitivity analyses to examine whether the conclu-
sions were affected by different assumptions, and therefore the de-
cisions regarding the eligibility and analysis of the studies. Where
possible, we analysed results to test for differences with the follow-
ing adjustments:
• if another analysis method (risk ratio) was used;
• studies with high risk of bias were excluded;
• studies with a large sample size were excluded;
• the early studies of IVF (pre-1990) were excluded, as
ovulation stimulation protocols were still being developed and
natural cycle IVF success rates may be lower than current natural
cycles.
In cases of high heterogeneity we used the random-effects model
and compared the results with those using the fixed-effect model;
R E S U L T S
Description of studies
See:Characteristics of included studies, Characteristics of excluded
studies, Characteristics of ongoing studies.
Results of the search
The search was conducted in July 2013. Searching each database
as stated in Appendix 1; Appendix 2; Appendix 3; Appendix 4;
Appendix 5; Appendix 6; Appendix 7; Appendix 8; and Appendix
9 resulted in a total of 864 articles of which EndNote removed
247 duplicates, leaving 617 articles. After screening the title and
abstract, a total of 36 appeared eligible for the review (Table 1).
Seven further duplicates were removed. The remaining 29 articles
were retrieved in full text or as an abstract, protocol or clinical
trial report. Seventeen reports that did not meet our inclusion
criteria were excluded. Of the 12 reports that met our criteria,
five were abstracts or preliminary results of a published full text
and one (Zhang 2013) was an ongoing study. We unsuccessfully
tried to contact the author for additional information. One study
was a conference presentation (Bensdorp 2013) and further data
are awaited. Overall, we included six studies. See: the study flow
diagram (Figure 1).
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Figure 1. Study flow diagram.
10Natural cycle in vitro fertilisation (IVF) for subfertile couples (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
A total of six randomised controlled trials, described in 11 publica-
tions, were eligible for inclusion. The total number of participants
was 788. The studies were conducted in China, Denmark, Italy,
theUnitedKingdom,TheNetherlands and theUnited States.One
of the included abstracts (Levy 1991) did not report data suitable
for meta-analysis. Attempts to contact the authors for clarifica-
tion were unsuccessful, so per woman data were not available. The
largest study (Bensdorp 2013) accounted for over half the partic-
ipants in the review (396); this study had three intervention arms
of which only two are included in this review. Bensdorp 2013 has
not completed follow up, but has reported preliminary findings
for over 95% of women.
Participants
The studies used differing inclusion and exclusion criteria with
respect to participant age, treatment indication and cause of sub-
fertility. For details, see Characteristics of included studies. One
trial (Morgia 2004) only included women who were poor respon-
ders in previous IVF cycles. This could influence their findings
because poor responders are less likely to reach pregnancy in any
IVF protocol.
Interventions
A variety of protocols were used in the included trials. In the
natural cycles, no treatment was given in four studies (Ingerslev
2001; Levy 1991; MacDougal 1994; Morgia 2004), whereas in
one study (Lou 2010) humanmenopausal gonadotrophin (HMG)
150 IU/day was given intramuscularly as a modified natural cycle
protocol. In Bensdorp 2013 a GnRH antagonist was used and
FSH was continued up to the day of ovulation triggering.
In the stimulated cycles, Ingerslev2001 andMacDougal 1994 used
clomiphene citrate. In one study (Levy 1991), ovarian hyperstim-
ulation was started with luteal phase initiated GnRH suppression
followed by HMG administration. Morgia 2004 used a GnRH
agonist (0.05 mg buserelin) from the first day of the menstrual
cycle in combination with 600 IU FSH (Metrodin HP, Serono,
Italy) from the third day of the menstrual cycle as the stimulation
protocol. In one study (Lou 2010), a GnRH agonist (triptorelin
0.1 mg/day subcutaneously) was used in combination with re-
combinant FSH (Gonal-F®;Merck Sereno, Geneva, Switzerland)
150 to 300 IU/day as the stimulation protocol. In Bensdorp 2013,
controlled ovarian hyperstimulationwas startedwith 150 IUFSH.
Treatment was continued until at least 2 follicles > 18mm had de-
veloped. Ovulation was induced by 10.000 IU human chorionic
gonadotropin hormone (hCG).
Primary outcomes
Effectiveness: 2/6 included studies reported live birth rate per
woman (Bensdorp 2013; MacDougal 1994).
Adverse effects: 1/6 included studies reported ovarian hyperstim-
ulation syndrome (OHSS) per woman (Lou 2010).
Secondary outcomes
Effectiveness:
• 4/6 included studies reported clinical pregnancy rates per
woman. Two reported cumulative pregnancy ( Ingerslev 2001;
Morgia 2004) and two reported pregnancy after a single cycle
(Lou 2010; MacDougal 1994).
• 3/6 included studies reported ongoing pregnancy
(Bensdorp 2013, Lou 2010; MacDougal 1994);
• 2/6 included studies reported number of oocytes retrieved
per woman (Lou 2010; MacDougal 1994). In one trial (Ingerslev
2001), the number of oocytes retrieved after multiple treatment
cycles per woman was given. E-mails were sent to the author to
request the data from the first cycle only
• 0/6 included studies reported time from start of treatment
to live birth;
Adverse effects:
• 2/6 included studies reported multiple pregnancies per
treatment (Bensdorp 2013; MacDougal 1994)
• 0/6 included studies reported failure to cryopreserve
embryos;
• 2/6 included studies reported cycle cancellation rates per
woman (MacDougal 1994; Morgia 2004). Re-analysis was
required in one study (Morgia 2004) for results that were
reported as percentages rather than cycle cancellations per
treatment. In one trial (Ingerslev 2001), cycle cancellation rates
were only reported after multiple treatment cycles per woman. E-
mails were sent to the author to request the data from only the
first cycle
• 2/6 included studies reported gestational abnormalities
(ectopic pregnancy, fetal growth disorders, preterm births and
miscarriages) per woman (Lou 2010; MacDougal 1994). Data
for Bensdorp 2013 are awaited.
• 1/6 included studies reported cancellation of the treatment
(Lou 2010);
• 2/6 included studies reported cost effectiveness: Bensdorp
2013 reported directed medical costs per ongoing pregnancy and
Lou 2010 reported the sum of the treatment medication in yuan.
Data for Bensdorp 2013 on cost per birth of healthy singleton
are awaited.
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Excluded studies
Seventeen studies were excluded from the analysis. For details,
see Characteristics of excluded studies. Of these studies, 10 were
not truly randomised controlled trials (Adams 2004; Bassil 1999;
Groenewoud 2012; Hojgaard 2001; Jancar 2009; Lee 2008;
Paulson 1990; Pistorius 2006; Reyftmann 2007; Schimberni
2011). One study (Belaid 2005) compared assisted hatching ver-
sus no assisted hatching. Four studies (Karimzadeh 2012; Kim
2009; Rama Devi 2011; Strohmer 1997) compared two different
controlled ovarian hyperstimulation protocols for IVF. One study
included females of proven fertility for an egg donation program
(Mirkin 2004) and one study (Vidal 2013) compared interven-
tions in endometrial preparation for oocyte donation rather than
in IVF.
Risk of bias in included studies
The risk of bias of the included trials was judged (see
Characteristics of included studies). For details, see Figure 2; Figure
3. We tried to contact authors of the included studies for addi-
tional data on allocation, incomplete outcome data and selective
reporting.We received additional information from the authors of
two trials (MacDougal 1994; Morgia 2004), but for three studies
(Ingerslev 2001; Levy 1991; Lou 2010) we failed to receive any
information.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation
Four of the six included trials generated the random sequence by
computer or internet and were rated as at low risk of bias in this
domain. Two of the studies did not describe what method was
used for sequence generation and were rated as at unclear risk of
bias.
Allocation concealment
One trial (Bensdorp 2013) used remote allocation andwas rated as
at low risk of bias. Of the other five included trials, three reported
the use of envelopes (Ingerslev 2001; MacDougal 1994; Morgia
2004). After contacting the authors, two confirmed that the en-
velopes were numbered and opaque (MacDougal 1994; Morgia
2004). One trial (Ingerslev 2001) stated that the envelopes were
sealed. Attempts were made to contact the authors for specifica-
tion. In two trials (Levy 1991; Lou 2010) themethod of allocation
concealment was not stated and therefore was judged as unclear
of bias. Attempts were made to contact the authors.
Blinding
We judged that the lack of blinding would only affect the can-
cellation of the treatment due to patient motivation. Because no
other outcomes were likely to be influenced by blinding, all trials
were judged low risk of performance and detection bias related to
other outcomes.
Incomplete outcome data
In two trials (Lou 2010; MacDougal 1994) all randomised par-
ticipants were included in analysis and in two trials (Bensdorp
2013; Levy 1991) 94-99% of participants were included in anal-
ysis. These studies were rated as at low risk of attrition bias. One
trial (Ingerslev 2001), published as an abstract in 1998, stated that
167 patients participated in the study, whereas the full-text article
published in 2001 stated that 35 of these patients were enrolled in
a pilot study and were excluded from the final analysis; this study
was rated as at high risk of attrition bias. In one trial (Morgia 2004)
16% of women in the natural cycle group refused their treatment
assignment. This study was rated as at high risk of attrition bias.
Selective reporting
We could not obtain a protocol for five of the included studies,
therefore it was unclear whether they reported all expected out-
comes. Attempts were made to obtain protocols from the authors.
Bensdorp 2013 has published a protocol but has reported prelimi-
nary results only, and so the risk of selective reporting in this study
was rated as unclear.
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Other potential sources of bias
No other source of potential bias was detected in any of the in-
cluded studies.
Effects of interventions
See: Summary of findings for the main comparison Natural
cycle IVF versus standard IVF for subfertile couples
1. Natural cycle versus standard IVF
Primary outcomes
Effectiveness
1.1 Live birth rate per woman
See: Analysis 1.1; Figure 4
Figure 4. Forest plot of comparison: 1 Natural cycle IVF versus standard IVF, outcome: 1.1 Live births.
Two trials (Bensdorp 2013; MacDougal 1994) reported this out-
come. Bensdorp 2013 reported the cumulative live birth rate after
modified natural cycles compared with standard IVF. MacDougal
1994 reported the live birth rate after a single cycle of natural cycle
compared with standard IVF. There was no significant difference
in the live birth rate between the natural cycle and the standard
IVF groups (OR 0.68, 95% CI 0.46 to 1.01, 425 women, I2=
0%).
In a sensitivity analysis, the findings remained non-significant
when a risk ratio was calculated rather than an odds ratio.
Adverse effect
1.2 Ovarian hyperstimulation syndrome (OHSS) per woman
See: Analysis 1.2; Figure 5
Figure 5. Forest plot of comparison: 1 Natural cycle IVF versus standard IVF, outcome: 1.2 OHSS.
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There was only one trial (Lou 2010) that reported this outcome.
There was no significant difference between the groups (OR 0.19,
95% CI 0.01 to 4.06, 60 women).
No sensitivity analysis could be done.
Secondary outcomes
Effectiveness
1.3 Pregnancy rate per woman
See: Analysis 1.3; Figure 6
Figure 6. Forest plot of comparison: 1 Natural cycle IVF versus standard IVF, outcome: 1.3 Clinical
pregnancy.
Four studies reported clinical pregnancy rate. Two reported cumu-
lative pregnancy (Ingerslev 2001; Morgia 2004) and two reported
pregnancy after a single cycle (Lou 2010; MacDougal 1994).
When a fixed effect model was used, there was a significantly lower
pregnancy rate in the natural cycle group (OR 0.51, 95% CI
0.28 to 0.92, four studies, 351 women, I2=63%), with substantial
heterogeneity. When a random effects model was used, there was
no significant different between the groups (OR 0.52, 95% CI
0.17 to 1.61, four trials, 351 women, I2=63%)
The analysis was stratified by number of cycles (multiple versus
single). Using a random effects model, there was no significant
difference between the groups in the cumulative pregnancy rate
over up to three cycles (OR 0.44, 95% CI 0.06 to 3.25, two stud-
ies, 261 women, I2=84%). Nor was there any significant differ-
ence in the rate after a single cycle (OR 0.84, 95% CI 0.30 to
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2.37, two studies, 890 women, I2=0%). The high heterogeneity
for this analysis was attributable to a single study (Ingerslev 2001),
and exclusion of this study in a sensitivity analysis reduced the I2
measure to 0%. The reason for the heterogeneity was unclear.
Sensitivity analysis
• When relative risk (RR) was used in a sensitivity analysis,
rather than odds ratio (OR), no statistically significant difference
in pregnancy rates per woman was found (random effects model:
RR 0.60, 95% CI 0.23 to 1.53).
• One trial (Lou 2010) did not describe the method of
allocation concealment and was removed in a sensitivity analysis.
The result showed no statistically significant difference in
pregnancy rates per woman (random effects model: OR 0.39,
95% CI 0.08 to 1.89)).
• When the trial with the biggest sample size was removed in
a sensitivity analysis, no statistically significant difference in
pregnancy rates per woman was found (random effects model:
OR 0.36, 95% CI 0.09 to 1.51).
• None of the included trials were published before 1990,
therefore this sensitivity analysis could not be done.
• In a further sensitivity analysis, we assessed the effect of
including the largest trial in the review (Bensdorp 2013) in this
analysis of clincial pregnancy, using their data for ongoing
pregnancy (because data for clinical pregnancy are not yet
available for this trial). Findings were similar to the main
analysis, and remained sensitive to choice of statistical model,
though heterogeneity was reduced somewhat (I2=52%).
Subgroup analysis by treatment type
In subgroup analysis by treatment type, when a fixed effect model
was used, there was a significantly lower pregnancy rate in the
unmodified natural cycle group compared to the standard IVF
group (OR 0.39, 95% CI 0.19 to 0.80, three studies, 291 women,
I2= 69%), with substantial heterogeneity. When a random effects
model was used, there was no significant difference between the
groups (OR0.39, 95%CI 0.08 to 1.89, three studies, 291women,
I2=63%). Nor was there a significant difference in pregnancy rate
between the modified natural cycle group and the standard IVF
group, although there was only one relevant study (OR 1.00, 95%
CI. 0.33 to 3.02, 60 women).
1.4 Ongoing pregnancies
See: Analysis 1.4 and Figure 7.
Figure 7. Forest plot of comparison: 1 Natural cycle IVF versus standard IVF, outcome: 1.4 Ongoing
pregnancy.
Three trials reported ongoing pregnancies after one cycle (Lou
2010; MacDougal 1994) or multiple cycles (Bensdorp 2013) of
treatment.
There was no evidence of a statistically significant difference in
ongoing pregnancy rates per woman between natural cycle and
standard IVF (OR 0.72, 95% CI 0.50 to 1.05, three studies, 485
women, I2=0%).
Sensitivity analysis
• The findings remained non-significant when a risk ratio
was calculated rather than an odds ratio.
• Because only two trials recorded this outcome after one
cycle, there was no point in excluding one of them in a sensitivity
analysis.
• None of the included trials were published before 1990,
therefore this sensitivity analysis could not be done.
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1.5 Number of oocytes retrieved per woman
See: Analysis 1.5.
There was only one trial (Lou 2010) with this outcome, which re-
ported that significantly fewer oocytes were retrieved in the natural
cycle group (MD -4.40, 95% CI -7.87 to -0.93, 60 women). One
trial (Ingerslev 2001) recorded the number of oocytes retrieved af-
ter multiple treatment cycles. One trial (MacDougal 1994) stated
a mean of 1 with a standard deviation of 0, so the outcome was
not estimable.
No sensitivity analysis could be done.
1.6 Time from start of treatment to live birth
Time from start of treatment to live birth was not reported in any
of the included trials.
1.7 Number of cycles required to conceive per woman
No trials reported this outcome
Adverse effects
1.8 Multiple pregnancies per woman
See: Analysis 1.8.
Two trials (Bensdorp 2013; Ingerslev 2001) reported events for
this outcome. Both these trials administeredmultiple cycles. There
was no significant difference between the groups in multiple preg-
nancy rate (OR 0.76, 95% CI 0.25 to 2.31, 527 women, I2=0%).
Two trials (MacDougal 1994; Morgia 2004) reported no events
in either the natural cycle treatment or the stimulated cycle treat-
ment groups.
1.9 Gestational abnormalities per woman
See: Analysis 1.9. There was only one trial (Lou 2010) which re-
ported this outcome (OR 0.44, 95%CI 0.03 to 5.93, 18 women).
Two trials (MacDougal 1994; Morgia 2004) had no events and
therefore could not be included in analysis. Data for Bensdorp
2013 are awaited.No sensitivity analysis could be done.
1.10 Cryopreservation of embryos
The number of embryos frozen was not reported in any of the
included trials.
1.11 Cycle cancellation rates per woman
See: Analysis 1.11 and Figure 8.
Figure 8. Forest plot of comparison: 1 Natural cycle IVF versus standard IVF, outcome: 1.11 Cycle
cancellations.
Two trials reported cycle cancellation rates. Higher cycle cancella-
tion rates were associated with natural cycle treatment compared
to the stimulated treatment (OR 3.10, 95% CI 1.49 to 6.45, 159
women; I2 = 83%). The considerable heterogeneity was proba-
bly caused by the different treatment protocols and the differing
populations. MacDougal 1994 enrolled women≤ 38 years of age
with > one year infertility and spontaneous ovulatory cycles, and
used a clomiphene citrate protocol; whereasMorgia 2004 enrolled
women ≤ 43 years of age with regular menstrual cycles, primary
infertility and poor ovarian reserve, and used a microdose GnRH
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analogue flare protocol. Because of this considerable heterogene-
ity, we used a random-effects model, which showed no statistically
significant difference in cycle cancellation rates (OR 8.98, 95%
CI 0.20 to 393.66, 159 women; I2 = 83%).
Sensitivity analysis
• When RR was used in a sensitivity analysis, rather than
OR, there was no statistically significant difference found in
cycle cancellation rates (RR 4.66, 95% CI 0.26 to 84.85, 159
women; I2 = 77%).
• Because only two trials recorded this outcome, there was no
point in excluding one of them in a sensitivity analysis.
• None of the included trials were published before 1990.
1.12 Cost effectiveness
See: Analysis 1.12.
No studies reported cost-effectiveness, defined as the total cost to
reach pregnancy. One study (Bensdorp 2013) reported the direct
medical costs to achieve ongoing pregnancy (singleton and multi-
ple), which were EURO9,838 in the modified natural cycle group
and EURO5,723 in the IVF single embryo transplant group. One
study (Lou 2010) reported the cost of medication, and found that
costs (to achieve pregnancy) were significantly lower in the natural
cycle group (SMD -5.59, 95% CI -6.75 to -4.44, 60 women).
Data on the total cost to reach a healthy singleton birth are awaited
for Bensdorp 2013.
1.13 Cancellation of the treatment
There was only one trial (Lou 2010) that reported cancellation
due to patient motivation, but because there were no events data
were not estimable.
D I S C U S S I O N
Summary of main results
No evidence of a statistically significant difference was found be-
tween natural cycle and standard IVF in live birth rates. Findings
suggest that for a woman with a 53% chance of live birth using
standard IVF, the chance using natural cycle IVF would range
from 34% to 53%. Nor was there evidence of a statistically signif-
icant difference between natural cycle and standard IVF in rates
of OHSS, clinical pregnancy, ongoing pregnancy, multiple preg-
nancy, gestational abnormalities or cycle cancellations. One trial
reported the number of oocytes retrieved per woman, and found
that the rate was significantly lower in the natural cycle group.
There was insufficient data on cancellation of treatment due to
patient motivation or adverse effects. Findings on treatment costs
were inconsistent and more data are awaited. Findings for preg-
nancy rate and for cycle cancellation were sensitive to the choice
of statistical model, and suggested a benefit for the standard IVF
group when a fixed effect model was used.
The lack of fully-reported large scale RCTs and the use of different
treatment protocols in different trials made it difficult to draw
definite conclusions.
The trial judged not suitable for meta-analysis (Levy 1991) re-
ported significantly higher pregnancy rates in COH-IVF com-
pared to NC-IVF, and significantly higher cycle cancellation rates
in NC-IVF compared to COH-IVF. Other data that we judged
important but not suitable for pooling can be found in Table 2.
Overall completeness and applicability of
evidence
Of the six included trials, live birth rate was reported as an out-
come in only two studies (Bensdorp 2013; MacDougal 1994),
and OHSS in only one (Lou 2010). Four trials (Levy 1991; Lou
2010; MacDougal 1994; Morgia 2004) reported clinical preg-
nancy rate, and three (Bensdorp 2013, Lou 2010; MacDougal
1994) reported ongoing pregnancy. The number of oocytes re-
trieved was reported in two studies (Lou 2010; MacDougal 1994)
but because MacDougal 1994 reported a standard deviation of
0, data were not estimable and could not be pooled. The time
from start of treatment to live birth was not reported in any of
the included trials. No trials reported number of cycles to con-
ceive per woman. Multiple pregnancies were reported in four tri-
als (Bensdorp 2013; Ingerslev 2001; MacDougal 1994; Morgia
2004) but MacDougal 1994 andMorgia 2004 reported no events
so these data were not estimable and could not be pooled. The
number of embryos frozen was not reported in any of the included
trials. Cycle cancellation was reported in four of the included trials
(Levy 1991; Lou 2010;MacDougal 1994;Morgia 2004), but Lou
2010 reported no events which made the data not estimable. Ges-
tational abnormalities were reported in three trials to date (Lou
2010; MacDougal 1994; Morgia 2004), but MacDougal 1994
and Morgia 2004 reported zero events so the data were not es-
timable and could not be pooled. Cancellation of treatment due
to patient motivation was reported in one study (Lou 2010), but
there were no events recorded so the data were not estimable. Also,
because this outcome was only recorded in one study, the data
could not be pooled. Treatment costs were reported in only two
studies (Bensdorp 2013; Lou 2010, and did not include full costs
to pregnancy or live birth. Data for Bensdorp 2013 are awaited
for some of these outcomes.
These results could be applicable to fertility clinics as in most
studies the participants were similar to most women having a first
cycle of IVF. The study by Morgia included women who were
poor responders only, which is not a general subfertile population.
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Two studies did not include frequently used stimulation protocols
for IVF; stimulation with clomiphene citrate in IVF cycles is not
generally recommended.
As the data are currently limited, the results from this review are
unable to be translated into clinical practice.
Quality of the evidence
Five trials reported data suitable for meta-analysis. Almost all tri-
als were judged as at low risk of bias for random sequence gener-
ation, but three failed to adequately describe allocation conceal-
ment. Two were rated as at high risk of attrition bias, due to the
apparent failure to report the outcomes of one group of partici-
pants (Ingerslev 2001) and the refusal of 16% of women in one
group to accept their treatment assignment (Morgia 2004). There
was high heterogeneity for some analyses, possibly due to different
inclusion criteria for the participants and the difference in IVF
protocols used for controls.
It is helpful for trials to report cumulative pregnancy and live birth
rates, due to the difference in number of oocytes retrieved, and
because a COH-IVF treatment is a much greater burden for the
couple and therefore cannot be repeated as often as a natural cycle
IVF treatment. Moreover in clinical practice, it is not common to
give just one IVF treatment. Therefore, trials reporting cumulative
rates provide a more realistic comparison.
The overall quality of the evidence was rated using GRADEmeth-
ods and ranged from very low to moderate. The main limitation
was imprecision. Bensdorp 2013 has reported preliminary data
only and has yet to complete follow up, but data were available
for over 95% of women randomised .
Potential biases in the review process
We based our definition of the natural cycle and the standard
treatment on the literature and clinical expertise. We conducted
the search, extracted data and excluded studies according to that
definition. This may have introduced bias. We aimed to retrieve
all eligible studies, however unpublished studies may not have
been identified. Data were incomplete for Bensdorp 2013 and full
results are awaited.
Because of the small number of studies, we did not construct a
funnel plot. Therefore we were unable to visually estimate the
existence of other studies or publication bias. Because of the small
amount of data, we were also unable to subgroup the data as we
stated in the protocol.
Finally, using computation from percentages to create dichoto-
mous data may have introduced bias.
Agreements and disagreements with other
studies or reviews
Other reviews on the subject show similar results (Loutradis 2007;
Loutradis 2008; Pandian 2010; Pelinck 2009; Reyftmann 2007);
they conclude that natural cycle IVF seems promising but that
there is insufficient information for definite conclusions. Opti-
mistic data on natural cycle IVF treatment have been published,
but more data from good quality trials are needed and further data
from Bensdorp 2013are also awaited.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We wanted to provide a clear overview of the differences between
natural cycle IVF and standard IVF so subfertile couples could
judge which treatment suited their preferences. Because the five
included trials in the meta-analysis (one included study was not
suitable) used different protocols and different study populations,
we could not come to clear conclusions. Because of the difference
in subfertility causes, there is no IVF treatment ideal for all cou-
ples. The situation and personal preferences of the women should
therefore be taken into consideration and women should be well
informed when choosing a specific treatment. For couples with
male factor subfertility, which is 20% of all causes of subfertil-
ity (Sharlip 2002), natural cycle IVF may be particularly suitable.
Treating a healthy female in a couple with male factor subfertility
can be considered a psychological burden for the male and both a
psychological and physical burden for the female.
Implications for research
Large scale randomised controlled trials are required comparing
natural cycle IVF with standard IVF. Outcomes should be cumu-
lative live birth rates, the number of treatment cycles per woman
necessary to reach live birth, treatment costs and adverse effects of
the treatment. Different treatment protocols and different causes
of subfertility should be subgrouped within the same trial so a
sensitivity analysis can be conducted. The data should be mea-
sured per woman, so a clear overview can be given on cumulative
pregnancy rates of different IVF treatments. Only then is it fair to
compare improvements in outcomes with the different IVF treat-
ments.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bensdorp 2013
Methods Multicentre randomised controlled trial (17 centres in the Netherlands): trial acronym
INeS
603 couples randomised, of whom 395 were randomised to comparisons of interest in
current review
Conducted Jan 2009 to Feb 2011
Follow-up 12 months
Participants Included: Couples with female aged between 18 and 38 years, diagnosed with unex-
plained or mild male subfertility, failure to conceive within at least 12 months of un-
protected intercourse and a poor prognosis. A poor prognosis was defined as a chance
of spontaneous pregnancy within 12 months below 30% or failure to conceive within
at least 3 years of unprotected intercourse. Mild male subfertility was defined as pre-
wash total motile sperm count above 10 million or a post-wash total motile sperm count
above 1 million
Excluded: Women with PCOS/anovulatory cycles, severe endometriosis, double sided
tubal pathology or serious endocrine illness
Interventions 1. Modified natural cycle (MNC) IVF x six cycles: the oocyte that developed sponta-
neously was used for IVF, minimally modified with a GnRH antagonist to prevent un-
timely ovulations, together with FSH to prevent collapse of the follicle
When a lead follicle with amean diameter of at least 14mmwas observed, daily injections
of 0.25 mg of a GnRH-antagonist together with 150 IU FSH were started. GnRH-
antagonist was continued up to and including the day of ovulation triggering. FSH was
continued up to the day of ovulation triggering (n=195 randomised, 194 analysed)
2. IVF with elective single-embryo transfer (SET) x 3 cycles, plus cryo-cycles within
12 months. Controlled ovarian hyperstimulation after down-regulation with a GnRH
agonist in a long protocol with a mid luteal start or with a fixed start antagonist protocol
starting on day two. Controlled ovarian hyperstimulation was started with 150 IU FSH.
Treatment was continued until at least 2 follicles > 18mm had developed. Ovulation
was induced by 10.000 IU human chorionic gonadotropin hormone (hCG). (n=203
randomised, 201 analysed)
Findings were evaluated over one year of follow up, within which time some women in
each group underwent cycles in addition to their allocated treatment, as follows:
1. MNC-IVF group (n=194)
Allocated treatment: MNC-IVF 640 cycles
Additional treatment: IUI 58 cycles, IVF MNC/SET/double embryo transfer (DET):
34 cycles, IVF SET 34 cycles, IVF DET<7 cycles, cryo cycles: 9
2. IVF-SET group (n=201)
Allocated treatment: IVF-SET 303 cycles, frozen cycles 147,
Additional treatment: IUI cycles 35, IVF MNC/SET/DET 4 cycles, IVF SET 1 cycle
[3. The study also included a group undergoing IUI with COH x 6 cycles (n=207
randomised, 207 analysed). This group were not included in the current review]
24Natural cycle in vitro fertilisation (IVF) for subfertile couples (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bensdorp 2013 (Continued)
Outcomes Birth of healthy singleton (term, birth weight >5th percentile, no congenital anomalies,
normal development up to 6 weeks), multiple pregnancy, clinical pregnancy, ongoing
pregnancy, time to pregnancy, neonatal and pregnancy complications, cost-effectiveness
Notes Funding: Netherlands Organization for Health Research and Development (ZonMw)
and Zorgverzekeraars Nederland (ZN)
In this review we reported data from the 2013 ESHRE slide presentation, which are
95% complete. Follow up is incomplete for 7/194 in the MNC group and 8/201 in the
standard IVF group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central internet-based randomisation pro-
gramme
Allocation concealment (selection bias) Low risk Central internet-based randomisation pro-
gramme
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysed by ITT. Incomplete follow-up for
7/194 in MNC group and 8/201 in stan-
dard IVF group (4%)
Selective reporting (reporting bias) Unclear risk Reported only in abstract/slide presenta-
tion so far and not all outcomes reported
yet (numbers inconsistent between the pre-
sentations)
Other bias Low risk Baseline characteristics of two groups were
similar. Reported only as abstract/slide pre-
sentation but no evidence of likely bias
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Ingerslev 2001
Methods Randomised controlled trial (block randomisation, five patients in each block)
Performed between August 1 and December 31, 1997
Informed consent obtained
Participants Fertility Clinic and Perinatal Epidemiological Research Unit, Department of Obstetrics
and Gynaecology, Aarhun University Hospital, Skejby Sygehus, Aarhus, Denmark
As stated in the article: among 564 couples waiting for IVF or ICSO treatment, 196
were invited to participate in the study, fulfilling the following criteria: female age < 35,
unexplained infertility, tubal factor or due to severe male factor with indication for ICSI,
regular menstrual cycle, presence of two ovaries and no previous IVF treatment. Of these,
29 did not respond, 35 were enrolled in a pilot study so 132 couples participated in the
present study
Unstimulated group:
• Mean age (years): 30.71 ± 2.50
• Duration of infertility (years): 4.54 ± 1.88
• Cycle length (days): 28.13 ± 3.52
• Cycle variation (days): 1.59 ± 1.33
• Primary infertility: 43
• Secondary infertility: 21
Clomiphene citrate group:
• Mean age (years): 30.19 ± 2.85
• Duration of infertility (years): 4.19 ± 2.03
• Cycle length (days): 28.31 ± 1.63
• Cycle variation (days): 1.79 ± 1.29
• Primary infertility: 46
• Secondary infertility: 22
Interventions Unstimulated cycle IVF versus stimulated cycle IVF
Unstimulated cycle group (64) received no treatment. When the dominant follicle
reached a diameter of≥17 mm,HCG (Pregnyl®; 5000 IU) was given for a timed oocyte
retrieval 35 - 36 hours later
The stimulated group (68) received clomiphene citrate (Clomivid®; Astra, Denmark)
100 mg from cycle day 3-7. When the dominant follicle reached a diameter ≥ 20 mm,




Cycles with embryo transfer
Total number of embryos transferred
Live intrauterine pregnancy rate per started cycle
Live intrauterine pregnancy rate per embryo transfer
Implantation rate.
Notes Author was unable to provide additional information, contact author again for update
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Ingerslev 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Block randomisation was used, with five
patients in each block. Does not state
method of randomisation
Allocation concealment (selection bias) Unclear risk A sealed envelope method was used, does
not state opaque
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome measurement is not likely to
be influenced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Results of 35 pilot patients are not reported
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other sources of bias were found
Levy 1991
Methods Prospective randomised crossover study
Participants George Washington University Medical Center, Washington, DC
As stated in the abstract, 31 IVF-ET candidates with regular ovulatory menstrual cycles
and no male factor have enrolled thus far
Interventions Natural cycle versus stimulated cycle IVF
In the natural cycle, 4000 IU hCGwas given in an effort to precede the endogenous LH
surge
In the stimulated cycle, luteal phase initiated GnRH suppression was followed by human
menopausal gonadotropin (10.000 IU) administration
Outcomes Pregnancy rates, cancellation rates, oocyte retrieval and fertilisation rate
Notes Stated as ongoing. Attempts to contact any of the authors failed
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Does not state method of randomisation. No
further information obtained
Allocation concealment (selection bias) Unclear risk Method not stated
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Levy 1991 (Continued)
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influenced
by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome measurement is not likely to be
influenced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Thirty-one patients included, 16 patients un-
derwent natural cycle and 13 underwent the
stimulated cycle; 2 patients are missing; 94%
of participants included in analysis
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other sources of bias were found
Lou 2010
Methods Prospective, randomised controlled trial
Performed between August 2006 and April 2008
Informed consent obtained
Sixty women randomised
Participants Ruijin Hospital, Shanghai, China
Inclusion criteria as stated:
• Women with a regular menstrual cycle
• age < 35
• no previous IVF treatment
• a baseline serum FSH concentration < 10 IU/l
• a regular and proven menstrual cycle of 28 - 30 days
• a BMI of 18 - 28 kg/m2
• tubal pathology as the indication of IVF treatment
Interventions Modified natural cycle IVF versus controlled ovarian hyperstimulation IVF
The modified natural cycle treatment as stated:
If the serum estradiol concentration was < 50 pg/ml, HMG 150 IU/day was given IM,
by a nurse or doctor, starting on the third day of the menstrual cycle; patients whose
serum estradiol concentration was > 50 pg/ml were removed from the study. The number
and size of ovarian follicles in were monitored by transvaginal ultrasonography on the
second day of stimulation. No gonadotrophin agonist or antagonist was given at any
time during the treatment cycle
The COH treatment as stated:
AGNRH agonist (triptorelin 0.1 mg/day SC) was self-administered by the patients from
day 21 of themenstrual cycle (7 days after ovulation), before the IVF cycle. Recombinant
FSH (Gonal-F®; Merck Sereno, Geneva, Switzerland) 150 - 300 IU/day was then self
administered by the patients from day 2 of the menstrual cycle, at which time the dose
of GNRH agonist was reduced to 0.05 mg/day. On the second day of the menstrual
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Lou 2010 (Continued)
cycle and on alternate days subsequently, the number and size of ovarian follicles in the
patients were monitored by transvaginal ultrasonography and measurement of serum
estradiol was carried out. The daily dose of recombinant FSH was adjusted according
to the serum estradiol level and the number and size of ovarian follicles. If the rate of
development follicles was greater or less than expected, the FSH dose was decreased or
increased, respectively, by 75 IU/day
In both groups, HCG 10000 IU was administered at a predetermined time of the day




Number of oocytes retrieved
Medication cost
Notes No additional data from the author were obtained.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated set of random num-
bers
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome measurement is not likely to
be influenced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other sources of bias were found
MacDougal 1994
Methods Randomised controlled trial
Informed consent obtained
Participants Hallam Medical Centre, The London Women’s Clinic, The Middlesex Hospital and
King’s College Hospital, London, United Kingdom
30 patients with the following inclusion criteria:
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MacDougal 1994 (Continued)
• age ≤ 38 years
• > 1 year infertility
• spontaneous ovulatory cycles (26 to 34 day length with < 4 days difference from
cycle to cycle and a midluteal phase P > 10 ng/mL (30 nmol/l))
• normal semen analysis (volume > 2 mL, count > 20 x 106/mL, > 40% motile, >
60% normal morphology)
Interventions Natural cycle versus clomiphene citrate stimulated cycles
The natural cycle group (n=14) received no treatment, whereas the clomiphene citrate
group received 100 mg during cycle day 2-6
All patients had an ultrasound scan (US) on day 2 and 7, followed by daily scans once
the leading follicle reached a size of 14 mm in diameter. Serum LH and E2 concen-
trations were measured daily from day 7 of the cycle. When the mean diameter of the
dominant follicle reached 17 mm, hCG, 5000 IU, was administered and US-directed
oocyte collection was performed 35 hour later
Outcomes Number of patients reaching oocyte recovery




Notes Author stated: patients were randomised using computer generated numbers to assign
patients to treatment arm with concealment in brown sealed opaque envelopes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer selected random numbers were
used
Allocation concealment (selection bias) Low risk After contacting the author, she stated the
use of ’brown paper opaque envelopes that
were numbered individually’
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome measurement is not likely to
be influenced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Unclear risk No protocol available
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MacDougal 1994 (Continued)
Other bias Low risk No other sources of bias were found
Morgia 2004
Methods Randomised controlled trial
Performed between January 2000 and July 2002
Informed consent received
Participants Bioroma Center, Rome, Italy
One hundred and forty women with the following inclusion criteria:
• age ≤ 43 years
• regular menstrual cycles (26-39 days)
• primary infertility
• poor ovarian reserve
• had undergone a previous IVF cycle
Interventions Natural cycle IVF versus IVF with controlled ovarian hyperstimulation
The natural cycle treatment as stated:
The follicle size was monitored by transvaginal ultrasound scan daily from the 7th day
of the cycle to measure follicular structures and endometrial thickness and morphology.
When a follicle reached 16 mm in diameter, ovulation was triggered with hCG, 10,000
IU (Profasi HP 5000, Serono, Italy)
The COH treatment as stated:
Patients undergoing controlled ovarian hyperstimulation with the microdose GnRH
analog flare protocol group were treated with 0.05 mg buserelin (Suprefact; Hoechst,
Berlin, Germany) SC twice daily from the 1st day of the menstrual cycle and FSH, 600
IU (Metrodin HP, Serono, Italy) daily from the 3rd day of the menstrual cycle. Follicle
size was measured daily by ultrasound and plasma levels of E2 were measured from the
7th day of stimulation. From this stage, the dose of pFSHwas adjusted, depending on the
individual response of each patient. When at least 2 follicles reached 16 mm in diameter,
ovulation was triggered with hCG, 10,000 IU (Profasi HP 5000, Serono, Italy)
Outcomes Number of oocytes retrieved
Pregnancy rate per cycle
Pregnancy rate per transfer
Implantation rate
Notes Author stated: For randomisation we used a list of random numbers in sealed opaque
envelopes given to patients
Re-analysis was required for data per woman
Pregnancy rate:
Out of 59 NC patients, 40.7% had a transfer so (59 x 40.7) / 100% = 24 transfers
Out of 24 transfers, 4.2% got pregnant so (24 x 4.2) / 100% = 1 pregnancy in NC
Out of 70 COH patients, 71.4% had a transfer so (70 x 71.4) / 100% = 50 transfers
Out of 50 transfers, 4.0% got pregnant so (50 x 4.0) / 100% = 2 pregnancies in COH
Cycle cancellation:
Out of 59 NC patients, 72.9% had an oocyte retrieval; therefore we assume 27.1% had
a cycle cancellation. So (59 x 27.1) / 100% = 16 cycle cancellations for NC
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Morgia 2004 (Continued)
Out of 70 COH patients, 82.8% had an oocyte retrieval; therefore we assume 17.2%
had a cycle cancellation. So (70 x 17.2) / 100% = 12 cycle cancellations for COH
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patients were randomised according to
a computer generated number sequence at
the time that their cycle was scheduled
Allocation concealment (selection bias) Low risk After contacting the author, he stated the
use of a ’list of random numbers in sealed,
opaque envelopes given to patients’
Blinding of participants and personnel
(performance bias)
Objective outcomes
Low risk The outcomes are not likely to be influ-
enced by any lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome measurement is not likely to
be influenced by any lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk Seventy womenwere randomly allocated to
each group: 11 women assigned to the nat-
ural-cycle group refused the randomization
and chose another treatment. Thus attri-
tion rate of 16% in one group
Selective reporting (reporting bias) Unclear risk No protocol available
Other bias Low risk No other sources of bias were found
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adams 2004 This is a cohort study
Bassil 1999 This is a cohort study
Belaid 2005 Not a comparison of interest; study compares assisted hatching versus no assisted hatching
Groenewoud 2012 This publication is a study protocol. It compares NC-frozen thawed embryo transfer (FET) versus artificial
cycle (AC)-FET, not a comparison of interest
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(Continued)
Hojgaard 2001 This is a retrospective study
Jancar 2009 Consecutive women were used, so not a randomised controlled trial
Karimzadeh 2012 Study compares 2 stimulation protocols: clomiphene citrate/gonadotropin/antagonist versus microdose GnRH
agonist flare protocols, so not a comparison of interest
Kim 2009 This study compares 2 different stimulation protocols: minimal stimulation using theGnRH antagonist cetrore-
lix and 150 IU recombinant human FSH (rhFSH; Gonal-F, Merck Serono SA) versus FSH 225 IU/day in
combination with cetrorelix (Cetrotide) 0.25 mg/day when the mean diameter of the lead follicle reached 13
to14 mm
Lee 2008 This is a retrospective study
Mirkin 2004 This study included females of proven fertility, so not a study population of interest. The outcome measures
are in gene expression, so no outcomes of interest
Paulson 1990 This is a study on unstimulated cycle IVF, not a comparison of interest
Pistorius 2006 This study uses questionnaires, so it is not a randomised controlled trial
Rama Devi 2011 This study compares 2 stimulation protocols, clomiphene citrate in combination with FSH versus the standard
long IVF protocol with a GnRH agonist, so not a comparison of interest
Reyftmann 2007 This is a review of the literature on natural cycle IVF
Schimberni 2011 Treatments were assigned to patients according to admission date, so not a randomised controlled trial
Strohmer 1997 This study compares two different stimulation protocols, an ultrashort gonadotrophin-releasing hormone ag-
onist versus a modified suppression protocol, so not a comparison of interest
Vidal 2013 This study compares a GnRHa agonists versus GnRH antagonists in endometrial preparation for oocyte dona-
tion, so not a comparison of interest
Characteristics of ongoing studies [ordered by study ID]
Zhang 2013
Trial name or title IVF Clinical Trial of Two Different Treatment Protocols
Methods Randomised controlled trial
Participants New Hope Fertility Center, New York, New York, United States
Inclusion criteria:
• Valid indication for IVF treatment
• First IVF attempt
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Zhang 2013 (Continued)
• Female age between 18 and 38 years
• Male partner 18 years of age or older
• Both partners STD free
• Must be able to understand that they may not become pregnant
Exclusion criteria:
• Not willing or able to sign the consent form
• Pre-existing medical condition preventing/interfering with IVF treatment
• Abnormal IVF screening tests, which includes Complete Blood Count, Varicella titer, Rubella titer,
PAP smear, Syphilis, HIV 1&2, Hepatitis B, Hepatitis C, Chlamydia, and Gonorrhea
• Abnormal pap smear
• Body Mass Index (BMI) falls below 18.5 or above 32.0
• Female participant with irregular menstrual cycles
Interventions IVF protocol and minimal stimulation IVF protocol
Outcomes Primary outcome parameter: Live birth
Secondary outcome parameters: Biochemical pregnancy, Clinical pregnancy, Ongoing pregnancy, Multiple
pregnancy rate, Miscarriage rate, Fertilisation rate, Number of oocytes, Number of embryos
Starting date December 2008
Contact information Henriette Julien, MD, info@ivfclinicaltrial.com
Notes Estimated completion date: January 2014
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D A T A A N D A N A L Y S E S
Comparison 1. Natural cycle IVF versus standard IVF




participants Statistical method Effect size
1 Live births 2 425 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.46, 1.01]
2 OHSS 1 60 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 4.06]
3 Clinical pregnancy 4 351 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.17, 1.61]
3.1 Cumulative rate over up
to 3 cycles
2 261 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.06, 3.25]
3.2 Single cycle 2 90 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.30, 2.37]
4 Ongoing pregnancy 3 485 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.50, 1.05]
5 Oocytes retrieved 1 60 Mean Difference (IV, Fixed, 95% CI) -4.40 [-7.87, -0.93]
8 Multiple pregnancies 2 527 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.25, 2.31]
9 Gestational abnormalities 1 18 Odds Ratio (M-H, Fixed, 95% CI) 0.44 [0.03, 5.93]
11 Cycle cancellations 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
11.1 NC-IVF versus
stimulated cycle IVF
2 159 Odds Ratio (M-H, Random, 95% CI) 8.98 [0.20, 393.66]
12 Costs 1 60 Std. Mean Difference (IV, Fixed, 95% CI) -5.59 [-6.75, -4.44]
13 Subgroup analysis: Clinical
pregnancy rate by intervention
4 351 Odds Ratio (M-H, Random, 95% CI) 0.52 [0.17, 1.61]
13.1 NC IVF versus
stimulated cycle IVF
3 291 Odds Ratio (M-H, Random, 95% CI) 0.39 [0.08, 1.89]
13.2 MNC-IVF versus
stimulated cycle IVF
1 60 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.33, 3.02]
Analysis 1.1. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 1 Live births.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 1 Live births
Study or subgroup Natural cycle Standard IVF Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bensdorp 2013 92/194 113/201 96.3 % 0.70 [ 0.47, 1.04 ]
MacDougal 1994 0/14 2/16 3.7 % 0.20 [ 0.01, 4.54 ]
Total (95% CI) 208 217 100.0 % 0.68 [ 0.46, 1.01 ]
Total events: 92 (Natural cycle), 115 (Standard IVF)
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard IVF Favours natural cycle
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Analysis 1.2. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 2 OHSS.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 2 OHSS
Study or subgroup Natural cycle Standard IVF Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lou 2010 0/30 2/30 100.0 % 0.19 [ 0.01, 4.06 ]
Total (95% CI) 30 30 100.0 % 0.19 [ 0.01, 4.06 ]
Total events: 0 (Natural cycle), 2 (Standard IVF)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours natural cycle Favours standard IVF
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Analysis 1.3. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 3 Clinical pregnancy.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 3 Clinical pregnancy








1 Cumulative rate over up to 3 cycles
Ingerslev 2001 4/64 20/68 29.7 % 0.16 [ 0.05, 0.50 ]
Morgia 2004 7/59 7/70 30.2 % 1.21 [ 0.40, 3.68 ]
Subtotal (95% CI) 123 138 59.8 % 0.44 [ 0.06, 3.25 ]
Total events: 11 (Natural cycle), 27 (Standard IVF)
Heterogeneity: Tau2 = 1.74; Chi2 = 6.29, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.80 (P = 0.42)
2 Single cycle
Lou 2010 9/30 9/30 30.2 % 1.00 [ 0.33, 3.02 ]
MacDougal 1994 0/14 2/16 9.9 % 0.20 [ 0.01, 4.54 ]
Subtotal (95% CI) 44 46 40.2 % 0.84 [ 0.30, 2.37 ]
Total events: 9 (Natural cycle), 11 (Standard IVF)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Total (95% CI) 167 184 100.0 % 0.52 [ 0.17, 1.61 ]
Total events: 20 (Natural cycle), 38 (Standard IVF)
Heterogeneity: Tau2 = 0.76; Chi2 = 8.09, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.31, df = 1 (P = 0.58), I2 =0.0%
0.01 0.1 1 10 100
Favours standard IVF Favours natural cycle
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Analysis 1.4. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 4 Ongoing pregnancy.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 4 Ongoing pregnancy
Study or subgroup Natural cycle Standard IVF Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bensdorp 2013 92/194 113/201 88.7 % 0.70 [ 0.47, 1.04 ]
Lou 2010 8/30 7/30 7.8 % 1.19 [ 0.37, 3.85 ]
MacDougal 1994 0/14 2/16 3.4 % 0.20 [ 0.01, 4.54 ]
Total (95% CI) 238 247 100.0 % 0.72 [ 0.50, 1.05 ]
Total events: 100 (Natural cycle), 122 (Standard IVF)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard IVF Favours natural cycle
Analysis 1.5. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 5 Oocytes retrieved.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 5 Oocytes retrieved





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lou 2010 30 7.8 (4.5) 30 12.2 (8.6) 100.0 % -4.40 [ -7.87, -0.93 ]
Total (95% CI) 30 30 100.0 % -4.40 [ -7.87, -0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours standard IVF Favours natural cycle
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Analysis 1.8. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 8 Multiple pregnancies.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 8 Multiple pregnancies
Study or subgroup Natural cycle Standard IVF Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bensdorp 2013 5/194 5/201 66.5 % 1.04 [ 0.30, 3.64 ]
Ingerslev 2001 0/64 2/68 33.5 % 0.21 [ 0.01, 4.38 ]
Total (95% CI) 258 269 100.0 % 0.76 [ 0.25, 2.31 ]
Total events: 5 (Natural cycle), 7 (Standard IVF)
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.63)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours natural cycle IVF Favours standard IV
Analysis 1.9. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 9 Gestational abnormalities.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 9 Gestational abnormalities
Study or subgroup Natural cycle Standard IVF Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lou 2010 1/9 2/9 100.0 % 0.44 [ 0.03, 5.93 ]
Total (95% CI) 9 9 100.0 % 0.44 [ 0.03, 5.93 ]
Total events: 1 (Natural cycle), 2 (Standard IVF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard IVF Favours natural cycle
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Analysis 1.11. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 11 Cycle cancellations.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 11 Cycle cancellations








1 NC-IVF versus stimulated cycle IVF
MacDougal 1994 10/14 0/16 42.8 % 77.00 [ 3.75, 1581.71 ]
Morgia 2004 16/59 12/70 57.2 % 1.80 [ 0.77, 4.19 ]
Subtotal (95% CI) 73 86 100.0 % 8.98 [ 0.20, 393.66 ]
Total events: 26 (Natural cycle), 12 (Standard IVF)
Heterogeneity: Tau2 = 6.32; Chi2 = 5.93, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard IVF Favours natural cycle
Analysis 1.12. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 12 Costs.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 12 Costs







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lou 2010 30 1056 (111) 30 16776 (3921) 100.0 % -5.59 [ -6.75, -4.44 ]
Total (95% CI) 30 30 100.0 % -5.59 [ -6.75, -4.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.51 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours standard IVF Favours natural cycle
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Analysis 1.13. Comparison 1 Natural cycle IVF versus standard IVF, Outcome 13 Subgroup analysis: Clinical
pregnancy rate by intervention.
Review: Natural cycle in vitro fertilisation (IVF) for subfertile couples
Comparison: 1 Natural cycle IVF versus standard IVF
Outcome: 13 Subgroup analysis: Clinical pregnancy rate by intervention








1 NC IVF versus stimulated cycle IVF
Ingerslev 2001 (1) 4/64 20/68 29.7 % 0.16 [ 0.05, 0.50 ]
MacDougal 1994 (2) 0/14 2/16 9.9 % 0.20 [ 0.01, 4.54 ]
Morgia 2004 (3) 7/59 7/70 30.2 % 1.21 [ 0.40, 3.68 ]
Subtotal (95% CI) 137 154 69.8 % 0.39 [ 0.08, 1.89 ]
Total events: 11 (Natural cycle), 29 (Standard IVF)
Heterogeneity: Tau2 = 1.26; Chi2 = 6.53, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 1.17 (P = 0.24)
2 MNC-IVF versus stimulated cycle IVF
Lou 2010 (4) 9/30 9/30 30.2 % 1.00 [ 0.33, 3.02 ]
Subtotal (95% CI) 30 30 30.2 % 1.00 [ 0.33, 3.02 ]
Total events: 9 (Natural cycle), 9 (Standard IVF)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 167 184 100.0 % 0.52 [ 0.17, 1.61 ]
Total events: 20 (Natural cycle), 38 (Standard IVF)
Heterogeneity: Tau2 = 0.76; Chi2 = 8.09, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Chi2 = 0.93, df = 1 (P = 0.33), I2 =0.0%
0.5 0.7 1 1.5 2
Favours standard IVF Favours natural cycle
(1) Up to 3 cycles
(2) Single cycle
(3) Up to 3 cycles
(4) Single cycle
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A D D I T I O N A L T A B L E S
Table 1. Number of articles










Table 2. Additional data
Ingerslev 2001 Levy 1991
Natural cycle Stimulated cycle Natural cycle Stimulated cycle
Cycles 114 111 22 26
Clinical pregnancy rate 4 20 0 6
Oocytes retrieved 68 (0.92 ± 0.40) 174 (1.83 ± 1.15)
Cycle cancellations 40 16 6 1
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
EBM Reviews - Cochrane Central Register of Controlled Trials <1977 - present>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (1579)




6 intracytoplasmic sperm injection$.tw. (414)
7 assisted reproduct$.tw. (392)
8 ovulation induc$.tw. (455)
9 (ovari$ adj2 stimulat$).tw. (750)
10 superovulat$.tw. (134)




15 (ovari$ adj2 induction).tw. (26)
16 (stimulat$ adj3 cycle$).tw. (351)
17 (embryo$ or blastocyst$).tw. (2115)
18 or/1-17 (5663)
19 natural.tw. (5056)
20 (modified adj5 cycle$).tw. (49)





26 18 and 25 (151)
Appendix 2. EMBASE search strategy
Embase <1980 - present>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (48345)
2 in vitro fertili?ation.tw. (19220)
3 icsi.tw. (8227)
4 intracytoplasmic sperm injection$.tw. (5736)
5 ivf.tw. (21578)
6 assisted reproduct$.tw. (11542)
7 intrauterine insemination$.tw. (2224)
8 ovulation induc$.tw. (4130)
9 (ovari$ adj2 stimulat$).tw. (6205)
10 superovulat$.tw. (2898)




15 (ovari$ adj2 induction).tw. (260)
16 embryo$.tw. (280998)
17 blastocyst$.tw. (17376)
18 (stimulat$ adj3 cycle$).tw. (3768)
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19 or/1-18 (360701)
20 natural$.tw. (446575)





26 simple protocol.tw. (786)
27 no stimulation.tw. (1502)
28 ’not stimulated’.tw. (2468)
29 or/20-28 (466658)
30 19 and 29 (10077)
31 Clinical Trial/ (875792)
32 Randomized Controlled Trial/ (338076)
33 exp randomization/ (60804)
34 Single Blind Procedure/ (17075)
35 Double Blind Procedure/ (113402)
36 Crossover Procedure/ (36349)
37 Placebo/ (213772)
38 Randomi?ed controlled trial$.tw. (84127)
39 Rct.tw. (10976)
40 random allocation.tw. (1213)
41 randomly allocated.tw. (18390)
42 allocated randomly.tw. (1869)
43 (allocated adj2 random).tw. (717)
44 Single blind$.tw. (13064)
45 Double blind$.tw. (134437)
46 ((treble or triple) adj blind$).tw. (304)
47 placebo$.tw. (185409)
48 prospective study/ (226861)
49 or/31-48 (1310623)
50 case study/ (18825)
51 case report.tw. (240081)
52 abstract report/ or letter/ (860278)
53 or/50-52 (1114196)
54 49 not 53 (1274596)
55 30 and 54 (592)
56 (2010$ or 2011$ or 2012$ or 2013$).em. (3491034)
57 55 and 56 (148)
Appendix 3. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 -
present>
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (31238)




6 intracytoplasmic sperm injection$.tw. (4649)
7 assisted reproduct$.tw. (8118)
8 ovulation induc$.tw. (3251)
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9 (ovari$ adj2 stimulat$).tw. (4565)
10 superovulat$.tw. (2831)




15 (ovari$ adj2 induction).tw. (211)
16 (stimulat$ adj3 cycle$).tw. (3075)
17 (embryo$ or blastocyst$).tw. (256993)
18 or/1-17 (316114)
19 natural.tw. (314184)
20 (modified adj5 cycle$).tw. (577)




25 ’not stimulated’.tw. (2480)
26 no stimulation.tw. (1418)
27 or/19-26 (332104)
28 18 and 27 (6456)
29 randomized controlled trial.pt. (341704)




34 clinical trials as topic.sh. (162693)
35 randomly.ab. (189401)
36 trial.ti. (110617)
37 (crossover or cross-over or cross over).tw. (55740)
38 or/29-37 (857169)
39 exp animals/ not humans.sh. (3767737)
40 38 not 39 (790885)
41 28 and 40 (233)
Appendix 4. PsycINFO search strategy




4 clinical trials/ (6576)
5 placebo/ (3391)
6 exp Treatment/ (538852)
7 or/1-6 (819614)
8 natural cycle$.tw. (34)
9 7 and 8 (15)
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Appendix 5. MDSG search strategy
Keywords CONTAINS “natural cycle” or “natural cycles” or “modified ICSI” or “modified natural cycle” or “unstimulated ovaries” or
Title CONTAINS “natural cycle” or “natural cycles” or “modified ICSI” or “modified natural cycle” or “unstimulated ovaries”
Appendix 6. CINAHL search strategy
<inception - present>
1 (MH “Fertilization in Vitro”) OR “ivf”
2 TX intracytoplasmic sperm injection
3 TX icsi
4 S1 OR S2 OR S3
5 TX natural cycle
6 TX modified cycle
7 TX unstimulated cycles
8 S5 OR S6 OR S7
9 S4 AND S8
Appendix 7. ISI Web of Knowledge search strategy
<inception - present>
Natural cycle AND IVF or ICSI
Modified cycle AND IVF or ICSI






Appendix 9. PubMed search strategy
<inception - present>
(((((((((“Fertilization in Vitro”[Mesh]) AND “Sperm Injections, Intracytoplasmic”[Mesh]) AND “Ovulation Induction”[Mesh]) OR
ivf[tw]) OR Fertilization in Vitro[tw]) OR icsi[tw]) OR (stimulated cycle[tw] OR stimulated cycles[tw])) AND (natural cycle[tw]
OR natural cycle/mild[tw] OR natural cyclers[tw] OR natural cycles[tw])) OR (modified cycle[tw] OR modified cycles[tw])) OR
(unstimulated cycle[tw] OR unstimulated cycles[tw]) AND Randomized Controlled Trial[ptyp]
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Because of the small amount of data, we were unable to subgroup the data as we stated in the protocol.
During the exclusion process, we realised we did not report important exclusion criteria in the protocol, so we added them in the review:
• donor oocytes;
• frozen embryo transfer;
• animal studies.
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Medical Subject Headings (MeSH)
∗Pregnancy Rate; Fertilization in Vitro [∗methods; statistics & numerical data]; Infertility, Female [∗therapy]; Live Birth [epidemiol-
ogy]; Menstrual Cycle [∗physiology]; Ovarian Hyperstimulation Syndrome [epidemiology]; Ovulation Induction [∗methods]; Patient
Compliance [statistics & numerical data]; Randomized Controlled Trials as Topic
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